SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Tempus gives Merck multi-year access to de-identified clinical and molecular data to train AI models

Tempus and Merck announced a multi-year collaboration giving Merck access to Tempus's de-identified clinical and molecular data and its Lens platform, including GPU infrastructure to train and fine-tune models. The companies did not state a value.

CHICAGO, March 3, 2026 Tempus AI announced a multi-year strategic collaboration with Merck that gives the drugmaker access to Tempus's de-identified clinical and molecular data and its Lens platform, according to an analysis of the deal by IntuitionLabs.1

Terms of the deal

Merck gets multi-year access to the data. Merck researchers can use Lens Workspaces, backed by GPU infrastructure, to train and fine-tune specific models on multimodal real-world data.1 No official deal value was disclosed. The analysis says Tempus CEO Eric Lefkofsky's comments on a May 5, 2026 earnings call about agreements of more than $100 million were read as implying Merck's deal is large, but the range in that article is the author's inference, not a reported price.1

Background

Tempus announced a related expanded collaboration with Gilead on April 9, 2026, giving enterprise-wide access to its data library through Lens, starting with oncology. In 2025 Tempus announced a $200 million data and model deal with AstraZeneca and Pathos AI.

What it means for data sellers

The offer to Merck combines a dataset with a managed environment to use it, which keeps the data on the seller's platform. Sellers of regulated data may find that a workspace model is easier to defend than a data transfer. Pricing for these deals is rarely public, so sellers should gather comparable deals, not rely on published numbers.

How the deal came together

  1. Multi-year collaboration. Tempus announced the Merck collaboration on March 3, 2026.
  2. Data access. Merck receives multi-year access to Tempus's de-identified clinical and molecular data through the Lens platform.
  3. Model training. Merck researchers can use Lens Workspaces backed by GPU infrastructure to train and fine-tune specific models on multimodal real-world data.
  4. Value left unstated. No official figure was disclosed; an analysis site inferred a range from management earnings-call comments, which is an estimate and not a reported price.

Takeaways for companies with data

  • Pharma buyers want the data and the compute together, so sellers can package a workspace, not just files.
  • Public companies may comment on deal size on earnings calls without naming a price.
  • Treat third-party estimates of deal value as estimates.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. Tempus AI RWD Deals: Merck and Gilead 2026 Pricing Analysis (IntuitionLabs, 2026)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.